Lista de obras -

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome

artículo científico publicado en 2017

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

artículo científico publicado en 2016

A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System

artículo científico publicado en 2015

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

artículo científico publicado en 2018

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

artículo científico publicado en 2012

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

artículo científico publicado en 2014

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

artículo científico publicado en 2018

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

artículo científico publicado en 2016

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

artículo científico publicado en 2018

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

artículo científico publicado en 2015

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

artículo científico publicado en 2016

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

artículo científico

Episensitization: Defying Time's Arrow

artículo científico publicado en 2015

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients

scientific article published on 01 November 2019

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

artículo científico publicado en 2015

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

artículo científico publicado en 2016

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

artículo científico publicado en 2016

Just eat it: A review of CD47 and SIRP-α antagonism

artículo científico publicado en 2020

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

artículo científico publicado en 2016

Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system

artículo científico publicado en 2017

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

artículo científico publicado en 2017

No patient left behind: The promise of immune priming with epigenetic agents

artículo científico publicado en 2017

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

scientific article published on 24 May 2016

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

artículo científico publicado en 2016

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

artículo científico publicado en 2016

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

artículo científico publicado en 2016

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

artículo científico publicado en 2019

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

artículo científico publicado en 2017

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

artículo científico publicado en 2016

RRx-001 protects against cisplatin-induced toxicities.

artículo científico publicado en 2017

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

artículo científico publicado en 2016

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

artículo científico publicado en 2016

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

artículo científico publicado en 2016

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

artículo científico publicado en 2020

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

artículo científico publicado en 2015

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

artículo científico publicado en 2015

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

artículo científico publicado en 2017

Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military

artículo científico publicado en 2015

TGF-beta: a master immune regulator

scientific article published on 12 April 2020

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

artículo científico publicado en 2016

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

artículo científico publicado en 2015

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

artículo científico publicado en 2017

The war on cancer: a military perspective

artículo científico publicado en 2015

Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors

artículo científico publicado en 2012

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

artículo científico publicado en 2016

What's New in SCLC? A Review

artículo científico publicado en 2017

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial

artículo científico publicado en 2016

Lista de obras de

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

Episensitization: Defying Time's Arrow

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Just eat it: A review of CD47 and SIRP-α antagonism

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

No patient left behind: The promise of immune priming with epigenetic agents

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 protects against cisplatin-induced toxicities.

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military

TGF-beta: a master immune regulator

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

The war on cancer: a military perspective

Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

What's New in SCLC? A Review

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial